Biblio
Export 436 results:
Author Title Type [ Year
Filters: First Letter Of Keyword is R [Clear All Filters]
“Chronic Obstructive Pulmonary Disease as a Risk Factor for Cognitive Dysfunction: A Meta-Analysis of Current Studies.”, J Alzheimers Dis, vol. 52, no. 1, pp. 101-11, 2016.
, “Chronic Sleep Deprivation Exacerbates Learning-Memory Disability and Alzheimer's Disease-Like Pathologies in AβPP(swe)/PS1(ΔE9) Mice.”, J Alzheimers Dis, vol. 50, no. 3, pp. 669-85, 2016.
, “Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 839-45, 2016.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Clinical Dementia Rating Scale Detects White Matter Changes in Older Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 411-23, 2016.
, “Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes.”, J Alzheimers Dis, vol. 49, no. 3, pp. 695-705, 2016.
, “Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes.”, J Alzheimers Dis, vol. 49, no. 3, pp. 695-705, 2016.
, “Clinical utility of the informant AD8 as a dementia case finding instrument in primary healthcare.”, J Alzheimers Dis, vol. 49, no. 1, pp. 121-7, 2016.
, “Clinical utility of the informant AD8 as a dementia case finding instrument in primary healthcare.”, J Alzheimers Dis, vol. 49, no. 1, pp. 121-7, 2016.
, “Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk Score.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1169-77, 2016.
, “Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk Score.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1169-77, 2016.
, “Cohort Effects in the Prevalence and Survival of People with Dementia in a Rural Area in Northern Sweden.”, J Alzheimers Dis, vol. 50, no. 2, pp. 387-96, 2016.
, “Cohort Effects in the Prevalence and Survival of People with Dementia in a Rural Area in Northern Sweden.”, J Alzheimers Dis, vol. 50, no. 2, pp. 387-96, 2016.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “Course and Determinants of Anosognosia in Alzheimer's Disease: A 12-Month Follow-up.”, J Alzheimers Dis, vol. 51, no. 2, pp. 357-66, 2016.
, “The Cytome Assay as a Tool to Investigate the Possible Association Between Exposure to Extremely Low Frequency Magnetic Fields and an Increased Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 741-9, 2016.
, “Decreased Inter-Hemispheric Functional Connectivity in Cognitively Intact Elderly APOE ɛ4 Carriers: A Preliminary Study.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1137-48, 2016.
, “Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia.”, J Alzheimers Dis, vol. 50, no. 1, pp. 101-10, 2016.
, “Delusions in Patients with Alzheimer's Disease: A Multidimensional Approach.”, J Alzheimers Dis, vol. 51, no. 2, pp. 427-37, 2016.
, “Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer's Dementia Based on Apraxia Profiles.”, J Alzheimers Dis, vol. 49, no. 3, pp. 593-605, 2016.
, “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
, “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
, “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
, “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
, “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
,